Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Estrogen

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,017 result(s) found for: Estrogen. Displaying page 1 of 51.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-000053-34 Sponsor Protocol Number: 0473081 Start Date*: 2004-07-28
    Sponsor Name:Orion Corporation, Orion Pharma, Orionintie,
    Full Title: Comparison of continuous combined estrogen-progestin regimen in alleviation of estrogen deficiency symptoms of postmenopausal women. A randomized, double-blind, fixed dose, multicentre phase IIIb ...
    Medical condition: Postmenopausal estrogen replacement regimen is the therapy of choice for the alleviation of climacteric symptoms. During the past few years, continuous-combined hormone replacement therapy (HRT) ...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10027304 LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-004864-37 Sponsor Protocol Number: ASP-OP3-1 Start Date*: 2018-05-16
    Sponsor Name:Aspen Global Incorporated
    Full Title: A Multinational, Phase 3, Double-blind, Placebo-Controlled, Randomized Study to Assess the Efficacy and Safety of Ovestin in the Treatment of Symptoms of Vulvar and Vaginal Atrophy in Postmenopausa...
    Medical condition: Vulvovaginal atrophy associated with menopause
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10047782 Vulvovaginal atrophy LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004008-71 Sponsor Protocol Number: ELDORADO Start Date*: 2017-01-19
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: The effect of curcumin and piperine on the pharmacokinetics of tamoxifen in patients with estrogen receptor positive breast cancer ‘the ELDORADO study’
    Medical condition: Estrogen receptor positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001234-34 Sponsor Protocol Number: 118 Start Date*: 2020-04-08
    Sponsor Name:HUS Syöpäkeskus
    Full Title: Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Women with Breast Cancer Taking an Aromatase Inhibitor.
    Medical condition: Breast cancer, postmenopausal atrophic vaginitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10036398 Postmenopausal atrophic vaginitis LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Elderly Gender: Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000696-39 Sponsor Protocol Number: HNF1595-21 Start Date*: 2023-02-21
    Sponsor Name:Helse-Nord
    Full Title: Estrogen replacement therapy (ERT) for treatment of adolescent anorexia nervosa – An open label study
    Medical condition: Anorexia nervosa
    Disease:
    Population Age: Adolescents, Under 18 Gender: Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005685-12 Sponsor Protocol Number: 20070724 Start Date*: 2008-10-09
    Sponsor Name:Universitätsklinik für Psychiatrie und Psychotherapie, Klin. Abteilung f. Biologische Psychiatrie
    Full Title: The influence of hormone replacement therapy on the cerebral serotonin-1A receptor distribution and mood in postmenopausal women
    Medical condition: Healthy postmenopausal women receiving standard hormone replacement therapy are measured using positron emission tomography to investigate the effects of hormones on the cerebral serotonin-1A recep...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000073-23 Sponsor Protocol Number: CRAD001YIC04 Start Date*: 2012-05-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center, expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrin...
    Medical condition: Estrogen receptor positive locally advanced or metastatic breast cancer in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) NL (Completed) SE (Completed) NO (Completed) ES (Completed) DK (Completed) FI (Completed) BE (Completed) CZ (Prematurely Ended) IT (Completed) HU (Completed) IE (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-002337-22 Sponsor Protocol Number: AEZS-130-052 Start Date*: 2015-12-08
    Sponsor Name:Aeterna Zentaris GmbH
    Full Title: Confirmatory validation of oral macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the diagnosis of Adult Growth Hormone Deficiency (AGHD) in comparison with the Insulin Tolerance Test ...
    Medical condition: Diagnosis of Adult Growth Hormone Deficiency (AGHD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) DE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003981-42 Sponsor Protocol Number: 2012.2708 Start Date*: 2014-10-20
    Sponsor Name:University Medical Center Groningen [...]
    1. University Medical Center Groningen
    2. VUMC
    Full Title: Estrogen receptor and androgen receptor imaging in metastatic breast cancer patients
    Medical condition: Estrogen receptor positive metastatic breast cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003065-17 Sponsor Protocol Number: CRAD001Y24135 Start Date*: 2013-05-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive HER2 negative metastatic or locally ad...
    Medical condition: Estrogen receptor positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) NL (Completed) PT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-001716-38 Sponsor Protocol Number: 1404-BIO-019-MF Start Date*: 2017-04-26
    Sponsor Name:IVI BILBAO
    Full Title: Influence instillation plasma rich in growth factors in endometrial cavity
    Medical condition: Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type. Less than 5 mm Endometrio despite 10 days with standard doses of estrogen therapy (6...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003960-22 Sponsor Protocol Number: WOO2 Start Date*: 2021-03-15
    Sponsor Name:Medical University of Innsbruck
    Full Title: Prospective Window of opportunity trial of 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer
    Medical condition: (ER+) Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003757-28 Sponsor Protocol Number: CRAD001Y2201 Start Date*: 2013-02-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A three-arm, randomized, open label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen r...
    Medical condition: Estrogen receptor positive locally advanced or metastatic breast cancer in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) SE (Completed) GB (Completed) IE (Completed) DK (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-001179-39 Sponsor Protocol Number: 2005108 Start Date*: 2006-10-11
    Sponsor Name:Procter & Gamble Pharmaceuticals
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel-group, Multicentre, 24 week Study to Evaluate the Efficacy and Safety of Transdermal Testosterone (300 mcg/day) in Naturally Menopausal Wome...
    Medical condition: Hypoactive sexual desire disorder
    Disease: Version SOC Term Classification Code Term Level
    7.0 10020933 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000693-30 Sponsor Protocol Number: 56UCS2017 Start Date*: 2019-11-25
    Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA
    Full Title: EXemestane in Progesterone and/or Estrogen receptor positive epithelial ovarian cancer. A Randomized phase III Trial, EXPERT.
    Medical condition: Women with confirmed high grade serous or endometrial epithelial ovarian cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001624-17 Sponsor Protocol Number: 210321 Start Date*: 2021-07-21
    Sponsor Name:Karolinska University Hospital
    Full Title: Safety of oral micronized progesterone versus norethisterone acetate in continuous combination with oral estrogen as menopausal hormone therapy – a double-blind randomized study- PROBES study (Prog...
    Medical condition: Climacteric symptoms
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002326-39 Sponsor Protocol Number: 1-10-72-57-15 Start Date*: 2015-08-19
    Sponsor Name:Gynecology Department,Herning Hospital [...]
    1. Gynecology Department,Herning Hospital
    2. Medical Department, Kolding Hospital
    Full Title: The influence of fat intake, estrogen, age, and gender on postprandial lipds and glucose
    Medical condition: Healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004872 10050903 Postmenopausal symptoms LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000129-28 Sponsor Protocol Number: GO42784 Start Date*: 2021-08-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WIT...
    Medical condition: Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) SK (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) LV (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) SI (Trial now transitioned) BG (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000106-19 Sponsor Protocol Number: GO29689 Start Date*: 2015-12-10
    Sponsor Name:Genentech, Inc
    Full Title: A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF GDC-0810 VERSUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER RESISTANT TO AROMATASE INHIBITOR THERAPY
    Medical condition: Advanced or Metastatic ER+/HER2- Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001064-27 Sponsor Protocol Number: s55283 Start Date*: 2013-06-25
    Sponsor Name:University Hospitals Leuven
    Full Title: Placebo-controlled trial with vitamin D to prevent worsening/relieve aromatase inhibitor-induced musculoskeletal symptoms in breast cancer patients
    Medical condition: aromatase inhibitor-induced musculoskeletal symptoms in postmenopausal breast cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 03:08:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA